Sonnet BioTherapeutics Holdings, Inc.
SONN
$3.47
$0.092.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 5,276.34% | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 5,276.34% | -100.00% | -- |
| Cost of Revenue | 40.45% | -13.03% | 192.87% | 55.04% | -28.33% |
| Gross Profit | -40.45% | 13.03% | -41.69% | -55.21% | 27.21% |
| SG&A Expenses | -23.35% | 37.81% | 200.43% | 10.01% | 16.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.87% | 9.33% | 196.68% | -12.76% | -10.72% |
| Operating Income | -7.87% | -9.33% | -122.80% | 11.85% | 9.87% |
| Income Before Tax | -7.71% | -1,055.42% | -156.94% | 14.91% | 11.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.71% | -1,055.42% | -170.49% | 14.91% | 11.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.71% | -1,055.42% | -170.49% | 14.91% | 11.18% |
| EBIT | -7.87% | -9.33% | -122.80% | 11.85% | 9.87% |
| EBITDA | -7.91% | -9.35% | -123.11% | 11.86% | 9.88% |
| EPS Basic | 82.90% | -240.65% | 36.53% | 80.13% | 76.44% |
| Normalized Basic EPS | 82.90% | -240.65% | 39.71% | 80.13% | 76.44% |
| EPS Diluted | 82.90% | -248.37% | 36.53% | 80.13% | 76.44% |
| Normalized Diluted EPS | 82.90% | -248.81% | 39.71% | 80.13% | 76.44% |
| Average Basic Shares Outstanding | 529.70% | 579.18% | 326.12% | 328.38% | 277.07% |
| Average Diluted Shares Outstanding | 529.70% | 541.94% | 326.12% | 328.38% | 277.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |